Ascletis Pharma Inc. Oral GLP-1 Cuts HbA1c 1.7% Vs Placebo at 12 Weeks

Ascletis reported its oral small-molecule GLP-1, ASC30, cut HbA1c by placebo-adjusted 1.6—1.7% at 12 weeks and reduced body weight by 3.8—4.4% at 13 weeks in a 100-patient U.S. Phase II T2D study, with favorable GI tolerability and no hepatic safety signal.Material DetailsContext by AI AnalystThis…